ResMed Inc.
General ticker "RSMDF" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $38.6B (TTM average)
ResMed Inc. does not follow the US Stock Market performance with the rate: -26.0%.
Estimated limits based on current volatility of 0.0%: low 22.61$, high 22.61$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-08-20, amount 0.07$ (Y1.24%)
- Total employees count: 11370 (+7.3%) as of 2026
- US accounted for 63.6% of revenue in the fiscal year ended 2024-06-30
- Top business risk factors: Inability to compete, Healthcare consolidation and payment reform, Geopolitical risks, Public health crises, Clinical trial success
- Earnings for 12 months up through Q4 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-06-30 to 2027-06-30
- 2025-06-30 to 2026-06-30 estimated range: [19.07$, 28.26$]
- 2026-06-30 to 2027-06-30 estimated range: [20.83$, 30.56$]
Financial Metrics affecting the RSMDF estimates:
- Positive: with PPE of 23.0 at the end of fiscal year the price was neutral
- Positive: Operating cash flow per share per price, % of 54.27 > 24.19
- Positive: 22.58 < Operating profit margin, % of 32.75
- Positive: -7.11 < Investing cash flow per share per price, % of -6.20
- Positive: -16.84 < Industry operating profit margin (median), % of -11.08
- Negative: Industry operating cash flow per share per price (median), % of 1.65 <= 3.66
- Negative: 69.38 < Shareholder equity ratio, % of 73.01 <= 81.92
Short-term RSMDF quotes
Long-term RSMDF plot with estimates
Financial data
| YTD | 2023-06-30 | 2024-06-30 | 2025-06-30 |
|---|---|---|---|
| Operating Revenue | $4,222.99MM | $4,685.30MM | $5,146.33MM |
| Operating Expenses | $3,091.12MM | $3,365.40MM | $3,460.96MM |
| Operating Income | $1,131.87MM | $1,319.89MM | $1,685.36MM |
| Non-Operating Income | $-30.21MM | $-55.09MM | $-7.80MM |
| R&D Expense | $287.64MM | $307.52MM | $331.28MM |
| Income(Loss) | $1,101.66MM | $1,264.80MM | $1,677.57MM |
| Taxes | $204.11MM | $243.85MM | $276.84MM |
| Net Income(Loss)* | $897.56MM | $1,020.95MM | $1,400.72MM |
| Stockholders Equity | $4,129.90MM | $4,864.04MM | $5,967.86MM |
| Inventory | $998.01MM | $822.25MM | $927.71MM |
| Assets | $6,751.71MM | $6,872.39MM | $8,174.39MM |
| Operating Cash Flow | $693.30MM | $1,401.26MM | $1,751.59MM |
| Capital expenditure | $134.00MM | $114.86MM | $89.86MM |
| Investing Cash Flow | $-1,159.85MM | $-269.78MM | $-200.04MM |
| Financing Cash Flow | $422.87MM | $-1,119.29MM | $-606.25MM |
| Earnings Per Share** | $6.12 | $6.94 | $9.55 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.